comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 02:09:30 - browse：92

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

focus

WSS

Trump's false claims about Georgia's 2020 election long debunked

New definition of a human embryo proposed amid rapid advances

Liz Cheney makes 1st public comment since Trump's election interference indictments

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Lung cancer is America's deadliest cancer. Yet so few get screened

Evacuations in place as 3 wildfires burn in eastern Washington state

leisure time

comprehensive

explore

Apple is now the first public company to be valued at $3 trillion

Patient advocates sound warning on FDA proposal on salt intake

Hepatitis C has a cure — but many Americans still lack access to it

ActiGraph execs on goal of drug approvals with digital endpoints

What does generative AI mean for health care? We asked experts

Supreme Court to hear if Covid misinformation is protected speech

As demand for Covid shots wanes, Moderna seeks its next success

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

New air purifier tech could be key to improving indoor air quality

ALS treatment from Biogen, Ionis fails in study

hotspot

Galapagos to make CAR

As H5N1 spreads in cows, experts warn against drinking raw milk

New details revealed about Purdue's marketing of OxyContin

ActiGraph execs on goal of drug approvals with digital endpoints

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Listen: Racing for gene therapy & a pioneering approval

focus

focus

focus

leisure time